The insider sale is small in absolute terms, but the recent cluster of insider selling (4 sells in 30 days) warrants monitoring for any upcoming negative catalysts or data readouts. Watch for any material news or clinical trial updates that could explain the pattern.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 22 $29.68entry
- T+1 · 6mo ago +0.67%α +0.09% · $29.88
- T+5 · 6mo ago −1.95%α −3.61% · $29.10
- T+20 · 5mo ago +9.47%α +10.88% · $32.49
- T+60 · 3mo ago +21.63%α +18.44% · $36.10
Price Chart
How similar events traded
Executive Summary
Director David W. Nassif filed a Form 144 notice of intent to sell 10,000 common shares of Pharvaris N.V., with an estimated aggregate market value of $303,076. The shares were acquired as restricted stock on April 15, 2025, and the proposed sale is planned for the Nasdaq exchange. This is a relatively small sale relative to the company's $2.1B market cap, but it comes amid a recent cluster of insider selling (4 sells totaling $786K in the past 30 days), which may raise modest concern about insider sentiment ahead of any upcoming catalysts.
Key Facts
- Director David W. Nassif filed Form 144 to sell 10,000 shares of PHVS common stock.
- Estimated aggregate market value of the proposed sale is $303,076.
- Shares were acquired as restricted stock on April 15, 2025.
- Proposed sale is planned for execution on or after May 21, 2026, on the Nasdaq exchange.
- This filing follows 4 insider sells totaling $786K in the past 30 days.
- The sale represents a small fraction of the company's $2.1B market cap.
Financial Impact
Proposed sale of $303,076 in shares, representing approximately 0.014% of the company's $2.1B market cap.
Risk Factors
- Insider selling cluster may signal reduced confidence ahead of a catalyst.
- Form 144 is only an intent to sell; the sale may not be executed.
- No specific share price or valuation context provided for the proposed sale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-004931 |
| Document: 0001950047-26-004931-index.html | 0001950047-26-004931 |
| Document: 0001950047-26-004931.txt | 0001950047-26-004931 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers